Development

BioPharm International® spoke with Jon Ellis, CEO, Trenchant BioSystems, about the commercial landscape for cell therapies and how digitization is impacting the industry.

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule oral therapy for immunological diseases.

The agreement, which covers a period of five years, has been designed to offer a turnkey service to companies seeking faster time to market for ADCs and bioconjugates.

The industry is diversifying pipelines from traditional small-molecule drugs to embrace complex and exciting new modalities.

The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.

Novel nucleases with diverse properties represent promising solutions, emphasizing their potential to overcome current limitations in genome editing and therapeutic delivery.

TriLink’s CleanCap capping technology, to which Quantoom will have access in the new partnership, has been used in the majority of all approved COVID-19 mRNA and saRNA vaccines.

Nicholas Giovannone of Regeneron explained the strategies behind overcoming re-administration challenges in a recap of his presentation at ASGCT 2025.

Science is propelling advances and operational shifts in the bio/pharmaceutical industry.

BioPharm International® spoke with Oury Chetboun, CEO of Seekyo Therapeutics, to get his perspective on what impact new modalities and technology innovations are having on biopharmaceutical development.

The company’s presence at ASGCT included not only a booth on the show floor, but also one oral and nine poster presentations.

Webinar Date/Time: Wed, Jun 4, 2025 11:00 AM EDT

A letter of intent has been signed by the two companies for supply of artificial platelet raw material.

A late-breaking poster presented at ASGCT 2025 described the enhanced central nervous system transduction and safety of the vector.

A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.

Tevard's tRNA therapy appears to restore full-length dystrophin and motor function in a Duchenne muscular dystrophy model, showing promise for nonsense mutation treatments.

The company’s technology was used to create CAR-T cells that demonstrated the expression of complex CARs in a single DNA donor.

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

BioPharm International® spoke with Ryan Larson, PhD, SVP, Head of Research at Umoja BioPharma about how emerging modalities in cancer treatments, including cell therapies, are evolving.

As more originator biologics lose patent exclusivity in the next decade, a healthy biosimilars pipeline is necessary but requires market support.

Incorporating sustainable practices into process designs as early as possible ensures optimal performance.

The company hopes that its proprietary circVec technology platform will become a gold standard for nucleic acid and viral therapeutics.

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

This article provides an overview and introduction to the use of analytics in biopharmaceutical development and manufacturing.

Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.